US Patent

US7094781 — Sulfamides and their use as endothelin receptor antagonists

Composition of Matter · Assigned to Actelion Pharmaceuticals Ltd · Expires 2025-12-05 · 0y expired

Vulnerability score 20/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel sulfamides and their use as active ingredients in pharmaceutical compositions, particularly as endothelin receptor antagonists.

USPTO Abstract

The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

Drugs covered by this patent

Patent Metadata

Patent number
US7094781
Jurisdiction
US
Classification
Composition of Matter
Expires
2025-12-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.